Evidence map›Paper›PMID 23946461›Full record

ArticleJournal of virology2013

Vaccination against a virus-encoded cytokine significantly restricts viral challenge.

Meghan K Eberhardt, Ashlesha Deshpande, W L William Chang, Stephen W Barthold, Mark R Walter, Peter A Barry

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Viral manipulation of the host immune response.Current opinion in immunology · 2015
    Review
  12. Review
  13. Exploiting viral natural history for vaccine development.Medical microbiology and immunology · 2015
    Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Meghan K EberhardtCenter for Comparative Medicine, Department of Pathology and Laboratory Medicine, California National Primate Research Center, University of California, Davis, California, USA.
Ashlesha Deshpande
W L William Chang
Stephen W Barthold
Mark R Walter
Peter A Barry
University of California, Davis · USUniversity of Alabama at Birmingham · US

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Prevention of Primary HCMV Infection by Vaccinating against HCMV-Encoded IL-10R01AI049342 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI BARRY, PETER A, WALTER, MARK R · 2002 to 2017
$6.9M
STRUCTURE STUDIES ON PROTEINS THAT MODULATE IL-10 ACTIONR01AI047300 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WALTER, MARK R · 2001 to 2011
$3.4M
NIAID NIH HHS AI047300-S1NIAID NIH HHS R01 AI047300NIAID NIH HHS R01 AI049342NIAID NIH HHS R01 AI49342NIH HHS P51 OD011107
6 · The paper itself

Abstract

Identification of immune correlates of protection for viral vaccines is complicated by multiple factors, but there is general consensus on the importance of antibodies that neutralize viral attachment to susceptible cells. Development of new viral vaccines has mostly followed this neutralizing antibody paradigm, but as a recent clinical trial of human cytomegalovirus (HCMV) vaccination demonstrated, this singular approach can yield limited protective efficacy. Since HCMV devotes >50% of its coding capacity to proteins that modulate host immunity, it is hypothesized that expansion of vaccine targets to include this part of the viral proteome will disrupt viral natural history. HCMV and rhesus cytomegalovirus (RhCMV) each encode an ortholog to the cellular interleukin-10 (cIL-10) cytokine: cmvIL-10 and rhcmvIL10, respectively. Despite extensive sequence divergence from their host's cIL-10, each viral IL-10 retains nearly identical functionality to cIL-10. Uninfected rhesus macaques were immunized with engineered, nonfunctional rhcmvIL-10 variants, which were constructed by site-directed mutagenesis to abolish binding to the cIL-10 receptor. Vaccinees developed antibodies that neutralized rhcmvIL-10 function with no cross-neutralization of cIL-10. Following subcutaneous RhCMV challenge, the vaccinees exhibited both reduced RhCMV replication locally at the inoculation site and systemically and significantly reduced RhCMV shedding in bodily fluids compared to controls. Attenuation of RhCMV infection by rhcmvIL-10 vaccination argues that neutralization of viral immunomodulation may be a new vaccine paradigm for HCMV by expanding potential vaccine targets.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralCytomegalovirus InfectionsCytomegalovirus VaccinesDisease Models, AnimalInterleukin-10Macaca mulattaVaccinationVaccines, AttenuatedViral ProteinsVirulence FactorsVirus ReplicationAntibodies, NeutralizingAntibodies, ViralCytomegalovirus VaccinesInterleukin-10Vaccines, AttenuatedViral ProteinsVirulence Factors

Identifiers

PMID23946461
PMCPMC3807330
OpenAlexW2154443454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.